“…In a very inspiring study ( Cohen et al, 2015 ), Cohen et al showed that commendamide was indeed able to interact with GPCRs by acting as an agonist of the GPCR G2A/132 receptor, implicated in autoimmunity and atherosclerosis. These interesting structural properties, its biogenic origin and bioactivity ( Cohen et al, 2015 ; Lynch et al, 2017 ; Lynch et al, 2019 ; Piscotta et al, 2021 ), but also the presence of an N -(3-hydroxyacyl)amino acid scaffold, which is a structural motif found in many other interesting bioactive products ( Morishita et al, 1997 ; Nemoto et al, 1998 ; Fuqua and Greenberg, 2002 ; Grandclément et al, 2016 ; Lynch et al, 2019 ), make of commendamide, a metabolite at the cross-road of gut microbiota and host signaling, an exceptionally attractive target for chemical synthesis.…”